Jonathan Bernstein, MD
Allergy & Immunology · Cincinnati, OHNPI 1093713638
Payments from drug & device makers
Across 1,815 payments — averaging $2497.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$593K
- CSL Behring$588K
- AstraZeneca$468K
- Merck$333K
- Shire North American Group Inc$327K
- Takeda Pharmaceuticals U.S.A., Inc.$287K
- plus $1.9M from 50 others
Across 41 payments — averaging $2143.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$41K
- Novartis$36K
- Sanofi$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- CSL Behring$1K
- Sanofi-aventis U.S. LLC$983
What the payments were for
- Consulting fees$349,99143%
- Speaking & faculty fees$402,35450%
- Grants$8750%
- Travel & lodging$39,4825%
- Food & beverage$17,6002%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,533,752 in reported general payments places this provider in the 95th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 55 | $2,132,743 |
| HaegardaC1 Esterase Inhibitor | 22 | $499,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 157 | $123,479 |
| XolairOmalizumab | 11 | $63,928 |
| Dupixent PenDupilumab | 17 | $62,669 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $62,321 |
| Spiriva RespimatTiotropium Bromide | 53 | $47,410 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $21,275 |
| Cromolyn Sodium | 28 | $17,253 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $15,896 |
| Arnuity ElliptaFluticasone Furoate | 46 | $15,631 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,128 |
| AirsupraAlbuterol Sulfate/Budesonide | 12 | $9,092 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 52 | $8,238 |
| Qvar RedihalerBeclomethasone Dipropionate | 23 | $8,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $287,084 | $2,132,74355 claims |
| CSL BehringHaegarda, Privigen | $587,895 | $561,58034 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $185,938 | $160,384243 claims |
| Boehringer IngelheimSpiriva Respimat | $81,773 | $47,41053 claims |
| AstraZenecaSymbicort, Airsupra | $468,463 | $24,98871 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $78 | $17,25328 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $142,496 | $8,08423 claims |
| MerckDulera | $333,363 | $6,35713 claims |
| Mylan Inc.Wixela Inhub | $1,452 | $4,63634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 128 allergy & immunology providers in Ohio.
Other allergy & immunology in Cincinnati
- David BernsteinCincinnati$2.7M
- Justin GreiweCincinnati$1M
- Sheharyar DurraniCincinnati$953K
- Juan AboniaCincinnati$515K
- Gordon MyersCincinnati$346K
- Joshua BernsteinCincinnati$18K
- David TapkeCincinnati$17K
- Jeffrey RaubCincinnati$14K
- John SeyerleCincinnati$8K
- Heather HartmanCincinnati$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.